PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 11, 2025HemaSphere4 citationsOpen Access

Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN–HARMONY Alliance platform

View Full Paper
AOAdrián Mosquera OrgueiraMGMarta Sonia GonzálezMDMattia D’Agostino

Key Points

  • New machine learning models predict survival outcomes, improving personalized risk management in multiple myeloma.
  • The comprehensive model achieved a C-index of 0.667 for overall survival, indicating effective predictive power.
  • Utilizing the EMN–HARMONY cohort data of over 14,000 patients allowed for robust model validation and evaluation.
  • These ML-based scores surpass traditional staging systems, showing effectiveness across different patient populations.

Abstract

Abstract Traditional risk stratification in multiple myeloma (MM) relies on clinical and cytogenetic parameters but has limited predictive accuracy. Machine learning (ML) offers a novel approach by leveraging large datasets and complex variable interactions. This study aimed to develop and validate novel ML‐driven prognostic scores for newly diagnosed MM (NDMM), with the goal of improving upon existing ones. To this end, we analyzed data from the EMN–HARMONY MM cohort, comprising 14,345 patients, including 10,843 NDMM patients enrolled across 16 clinical trials. Three ML models were developed: (1) a comprehensive model incorporating 20 variables, (2) a reduced model including six key variables (age, hemoglobin, β2‐microglobulin, albumin, 1q gain, and 17p deletion), and (3) a cytogenetics‐free model. All models were internally validated using out‐of‐bag cross‐validation and externally validated with data from the Myeloma XI trial. Model performance was evaluated using the concordance index (C‐index) and time‐dependent area under the receiver operating characteristic curve (ROC‐AUC). The comprehensive model achieved C‐index values of 0.666 (training) and 0.667 (test) for overall survival (OS) and 0.620/0.627 for progression‐free survival (PFS). The reduced model maintained accuracy (OS: 0.658/0.657; PFS: 0.608/0.614). The cytogenetics‐free model showed C‐index values of 0.636/0.643 for OS and 0.600/0.610 for PFS. Incorporating treatment type and best response to first‐line treatment further improved performance. The new prognostic models improved over the International Staging System (ISS), Revised International Staging System (R‐ISS), and Second Revision of the International Staging System (R2‐ISS) and were reproducible in real‐world and relapsed/refractory MM, including daratumumab‐treated patients. This ML‐based risk stratification strategy provides individualized risk predictions, surpassing traditional group‐based methods and demonstrating broad applicability across patient subgroups. An online calculator is available at https://taxonomy.harmony-platform.eu/riskcalculator/ .

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Orgueira et al. (2025) studied this question.

synapsesocial.com/papers/68e9b1b5ba7d64b6fc132120https://doi.org/10.1002/hem3.70228
Ask AI
Helpful
Bookmark
Share
View Full Paper